Fc-saxatilin inhibits VEGF-induced permeability by regulating claudin-5 expression in human brain microvascular endothelial cells by 허지회
Contents lists available at ScienceDirect
Microvascular Research
journal homepage: www.elsevier.com/locate/ymvre
Fc-saxatilin inhibits VEGF-induced permeability by regulating claudin-5
expression in human brain microvascular endothelial cells
Hyun-Jung Choia, Na-Eun Kimc, Il Kwonc, Dukhwan Choic, Jayoung Kimc, Ji Hoe Heoa,b,c,⁎
a Integrative Research Center for Cerebrovascular and Cardiovascular diseases, Yonsei University College of Medicine, Seoul 03722, Republic of Korea
bDepartment of Neurology, Yonsei University College of Medicine, Seoul 03722, Republic of Korea
c Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul 03722, Republic of Korea







A B S T R A C T
The disruption of the blood–brain barrier influences the degree of brain damage and prognosis in cerebral
ischemia or other brain diseases accompanied by inflammation. Vascular endothelial growth factor (VEGF)
released during brain ischemia or inflammation has been implicated in the breakdown of the blood–brain barrier
by increasing endothelial permeability. Saxatilin, a disintegrin-containing RGD motif, has been reported to
disaggregate platelets via interactions with platelet integrins and to have a thrombolysis effect. Additionally, the
Fc–saxatilin fusion protein reduces vascular leakage in cerebral ischemia in mice. In this study, we show that
Fc–saxatilin prevents VEGF-induced permeability in human brain microvascular endothelial cells (HBMECs).
The activation of Src and Fak, downstream signaling proteins of VEGF in the induction of endothelial perme-
ability, was inhibited by Fc–saxatilin in HBMECs. The downregulation of a tight junction protein, claudin-5, at
the protein and mRNA levels by VEGF was recovered by Fc–saxatilin. Our findings suggest that Fc–saxatilin
attenuates VEGF-induced endothelial permeability via the regulation of downstream signaling, and this may
contribute to its protective effect against vascular leakage in the ischemic brain.
1. Introduction
Saxatilin is an RGD (Arg-Gly-Asp) motif-containing disintegrin iso-
lated from Korean snake (Gloydius saxatilis) venom (Hong et al., 2002).
Due to its high affinity to the platelet integrin αIIb β3 (glycoprotein IIb/
IIIa), saxatilin has been reported to have inhibitory effects on platelet
activation and aggregation in vitro (Jang et al., 2007). Saxatilin also
accelerates thrombolysis in a mouse model of carotid artery thrombosis
(Kwon et al., 2013). Additionally, the Fc–saxatilin fusion protein has a
protective effect against ischemia-induced vascular injury by inter-
acting with integrin αvβ3 on endothelial cells (Choi et al., 2017).
The disruption of the blood–brain barrier (BBB) in focal cerebral
ischemia is one of the most critical events contributing to cerebral
ischemia/reperfusion injury. Vascular endothelial growth factor (VEGF)
is involved in BBB leakage in the ischemic brain. VEGF is a mitogenic
growth factor associated with angiogenesis and a potent inducer of
endothelial permeability. The expression of VEGF is up-regulated in the
brains of both transient and permanent middle cerebral artery occlusion
models (Hayashi et al., 1997; Kovacs et al., 1996). While VEGF con-
tributes to vascular leakage and lesions at an early stage of the ischemic
brain, it ameliorates tissue damage by inducing angiogenesis in the
penumbra region at a later stage (Zhang et al., 2000). Several studies
have demonstrated that the antagonism of VEGF in the acute stage of
stroke reduces tissue injuries by suppressing vascular permeability in
the ischemic brain (van Bruggen et al., 1999), implicating VEGF in the
pathogenesis of stroke.
The promotion of permeability by VEGF is initiated by binding to
VEGF receptors and is mediated by several intermediate molecules,
including Src and Fak. Src is phosphorylated in response to VEGF.
Activated Src in turn regulates the expression or stability of junctional
proteins. A deficiency of Src or the blockade of Src phosphorylation
results in abnormal vascular permeability in response to VEGF (Eliceiri
et al., 1999). Fak, a kinase activated by integrins, also mediates VEGF-
induced vascular permeability (Chen et al., 2012). The genetic or
pharmacological inhibition of Fak activity in endothelial cells blocks
VEGF-induced permeability mediated by VEGF receptors and Src acti-
vation in vivo (Chen et al., 2012).
Claudin-5 is a tight junction protein and a major structural com-
ponent of the BBB. This tight junction protein mediates the selective
permeability of the BBB, and claudin-5 knockout mice show selective
BBB opening (Nitta et al., 2003). Its expression is dynamically regulated
by VEGF at the level of transcription in human brain endothelial cells
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(Argaw et al., 2009). The direct injection of VEGF in the mouse cerebral
cortex downregulates claudin-5 and induces the breakdown of the BBB
(Argaw et al., 2009). Interestingly, the inhibition of Src phosphoryla-
tion by a Src inhibitor, PP2, preserves claudin-5 expression and at-
tenuates BBB disruption in mouse ischemic brains (Bai et al., 2014).
VEGF signaling is associated with integrin signaling initiated by
interactions with the extracellular matrix. We thus investigated the
effect of Fc–saxatilin, a disintegrin, on VEGF-induced permeability in
brain endothelial cells. We evaluated whether the activation of Src and
Fak kinases by VEGF is affected by Fc–saxatilin. Lastly, we explored the
effect of Fc–saxatilin on VEGF-mediated claudin-5 disruption.
2. Materials and methods
2.1. Cell culture and reagents
Human brain microvascular endothelial cells (HBMECs) were pur-
chased from Neuromics (HEC02; Minneapolis, MN, USA). HBMECs
were maintained in ENDO-growth medium (MED001; Neuromics) or
endothelial growth medium (EGM)-2 (Lonza, Walkersville, MD, USA)
supplemented with 100 U/ml penicillin and 100 μg/ml streptomycin at
37 °C in humidified incubators with 5% CO2 and 95% room air.
HBMECs and HUVECs were used between passages three and seven.
HBMECs or HUVECs were treated by Fc-saxatilin diluted in PBS. VEGF
was purchased from R&D systems biotechnology (Minneapolis, MN,
USA). Human Immunoglobulin G4 (IgG4) Fc region was fused to N-
terminal of Saxatilin (pYK603) and the fusion protein was expressed in
CHO cells. Fc-Saxatilin was purified by protein A affinity column
(Mabselect Sure resion, GE, Chicago, IL, USA) and anion exchange
chromatography (AIEX; HiTrap Capto Q ImpRes, GE, Chicago, IL, USA).
2.2. Assay of endothelial cell monolayer permeability
The effect of hypoxia on endothelial monolayer permeability to
fluorescein isothiocyanate-conjugated 70-kDa dextran (FITC-dextran;
Sigma-Aldrich Chemicals, St. Louis, MO, USA) was assessed using
Transwell permeable membranes (24-well cell culture inserts) with a
0.4-μm pore size (Costar, Corning, NY, USA). Cells (105) were seeded on
gelatin-coated Transwell filters and allowed to grow for 5 days. The
cells were incubated with Fc–saxatilin (50 ng/ml, 100 ng/ml or 300 ng/
ml) or PBS only for 10min before exposure to VEGF (100 ng/ml). PBS
only treated cells served as control. The treated cells were then in-
cubated for 24 h. After 24 h, FITC-dextran 70 (70 kDa, 1mg/ml; Sigma)
was added to the upper compartment. 25 μl medium were removed
from every lower chamber of the transwell at 15min later and diluted
1:20 with the medium. The diluted samples were transferred into a
black 96-well plate (Costar, Corning, NY, USA) as triplicates and the
fluorescence intensity of FITC-dextran was measured using a fluores-
cence plate reader (BioTek Inc., Winooski, VT, USA).
2.3. Western blot
Cells cultured in 60-mm plates were washed with ice-cold phos-
phate-buffered saline (PBS) and lysed in 200 μl of RIPA buffer (50mM
Tris-HCl, 150mM NaCl, 1% sodium deoxycholate, 0.1% SDS, and 2mM
EDTA) containing proteinase inhibitors and phosphatase inhibitors
(GenDepot, Kathy, TX, USA). The lysates were centrifuged at 16,000×g
(Hanil Biomed Inc., Gwangju, Republic of Korea) for 15min. The cell
lysates were analyzed by SDS-PAGE on 8% or 10% gels and transferred
onto a polyvinylidene difluoride (PVDF) membrane (Millipore,
Burlington, MA, USA). Immunoblotting was performed with anti-
claudin-5 (Invitrogen Corp. Camarillo, CA, USA), anti-pFak, anti -Fak,
anti-pSrc (Cell Signaling Technology Inc., Danvers, MA, USA), anti-Src,
and anti-β-actin antibodies (Abs) (Santa Cruz Biotechnology, Santa
Cruz, CA, USA).
2.4. Immunostaining of claudin-5
Cells grown on gelatin-coated glass coverslips were washed once
with Dulbecco's phosphate-buffered saline (DPBS) and fixed with 4%
paraformaldehyde in PBS for 15min at room temperature. The cells
were then washed and permeabilized with 0.1% Triton X-100 in PBS for
12min at 4 °C. Next, the cells were incubated with 3% BSA in PBS for
30min at room temperature and with an anti-claudin-5 Ab (Invitrogen,
Carlsbad, CA, USA) in PBS containing 3% BSA overnight at 4 °C. The
cells were then washed three times for 5min with DPBS and incubated
with a 1:200 dilution of a FITC-conjugated secondary Ab in PBS con-
taining 3% BSA for 1 h at room temperature. Cells were washed with
DPBS once and then nuclei were stained with DAPI (1:5000). After
three washes for 5min with DPBS, the coverslips were drained and
mounted in a mounting solution (Dako, Santa Clara, CA, USA).
2.5. Quantitative real-time reverse transcription polymerase chain reaction
(qRT-PCR)
Total RNA was isolated from HBMECs using the RNeasy Kit (Qiagen,
Hilden, Germany). cDNA (20 μl) was synthesized from total RNA (1 μg)
using the AccuPower RocketScript Cycle RT PreMix (Bioneer Corp.,
Daejeon, Republic of Korea). The abundance of transcripts in each
cDNA sample was measured by real-time PCR with specific primers.
The reactions contained PowerSYBR Green PCK Master Mix (Applied
Biosystems, Foster City, CA, USA), 10 pmol both forward and reverse
Fig. 1. Fc–saxatilin inhibits VEGF-induced endothelial permeability. A) The
transwell cultured with human brain microvascular endothelial cells (HBMECs)
were pretreated with vehicle (PBS, 0) only or Fc-saxatilin (50, 100, or 300 ng/
ml) in the basal medium (0.5% FBS) for 10min and then exposed to VEGF
(100 ng/ml) for 24 h. Cells treated with only PBS served as a control. B) Human
umblical vein endothelial cells (HUVECs) cultured in transwell were pretreated
with PBS or Fc-saxatilin (100 or 300 ng/ml) for 10min. Cells were then treated
with VEGF (100 ng/ml) and incubated for 24 h. A Transwell permeability assay
was performed as described in materials and methods, and the diffused fluor-
escent tracer was measured and normalized by the control. All experiments
were assayed in triplicate and repeated three separate times with similar re-
sults. A representative of three experiments is shown (n=3); ***P < 0.0001
compared to PBS only- or VEGF only-treated cells.
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primers, and 1 μl of cDNA corresponding to 1 μg of total RNA. The re-
action conditions included 50 cycles of PCR amplification (95 °C for
10 s, 55 °C for 15 s, and 72 °C for 20 s) using a StepOne Plus (Applied
Biosystems) detection system. All results were normalized to GAPDH
mRNA levels. The following primers were used: human claudin-5 for-
ward, 5′-GTCCGCGAGTTTTACGACC-3′ and reverse 5′-GCTGAGTACTT
CACGGGGAA-3′; human GAPDH forward, 5′-ACCCAGAAGACTGTGGA
TGG-3′ and reverse, 5′-TCTAGACGGCAGGTCAGGTC-3′.
2.6. Statistical analysis
Data are expressed as means± standard error of the mean (SEM).
Statistical analyses were performed using GraphPad Prism 5.0
(GraphPad, La Jolla, CA, USA). Differences between two-groups were
evaluated using two-tailed Student's t-test. For all statistical analysis, a
P-value of< 0.05 was considered statistically significant.
3. Results
3.1. Fc–saxatilin prevents VEGF-induced permeability in human brain
endothelial cells
To determine the effect of Fc–saxatilin on VEGF-induced endothelial
permeability in the brain, we treated HBMECs with VEGF in the pre-
sence or absence of Fc–saxatilin. Intercellular permeability was mea-
sured by the leakage of FITC-dextran through the monolayer of
HBMECs after treatment. VEGF significantly increased the passage of
FITC-dextran across the endothelial monolayer, indicating its perme-
ability-promoting effect (Fig. 1). Fc–saxatilin efficiently blocked the
increase in endothelial permeability by VEGF in a dose-dependent
manner (Fig. 1).
3.2. Fc–saxatilin inhibits VEGF downstream signaling in HBMECs
VEGF regulates vascular permeability via downstream signaling
mediated by Src kinase. We thus assessed the effect of Fc–saxatilin on
Src activation. Src phosphorylation increased in response to VEGF in
HBMECs, consistent with the enhanced permeability (Fig. 2). Fc–sax-
atilin inhibited the phosphorylation of Src induced by VEGF in a dose-
dependent manner. Another downstream signaling protein that could
be activated by VEGF or integrin is focal adhesion kinase (Fak). The
genetic or pharmacological inhibition of Fak in endothelial cells blocks
VEGF-induced endothelial permeability and Src activation in vitro and
in vivo (Chen et al., 2012). We evaluated the activation of Fak by de-
tecting Fak phosphorylation in brain endothelial cells. VEGF induced
Fak phosphorylation significantly (Fig. 3). This induction was blocked
by Fc–saxatilin (Fig. 3). Taken together, these results suggest that
Fc–saxatilin inhibits the downstream signaling important for VEGF-in-
duced vascular permeability.
3.3. Fc-saxatilin reverses the claudin-5 reduction induced by VEGF in
HBMECs
To determine whether the protective effect of Fc–saxatilin on VEGF-
induced endothelial permeability is associated with changes in claudin-
5, we analyzed cell lysates after the treatment of HBMECs with VEGF in
the presence or absence of Fc–saxatilin. Claudin-5 was detected by
western blotting as a band at around 22 kDa and was strongly down-
regulated by VEGF (Fig. 4A and B). The reduction in the claudin-5
protein level was partially recovered in Fc–saxatilin-treated HBMECs
(Fig. 4A and B). Another tight junction protein, occludin, was not sig-
nificantly altered by VEGF in the absence or presence of Fc–saxatilin
(Fig. 4A). Immunofluorescence staining of HBMECs with a claudin-5-
Fig. 2. Fc–saxatilin attenuates the phosphorylation of Src induced by VEGF in
HBMECs. A) HBMECs were treated with pretreated with vehicle (PSB, 0) or Fc-
saxatilin (50, 100, or 300 ng/ml) in the basal medium (0.5% FBS) for 10min
and treated with VEGF (100 ng/ml) for 1 h. Control cells were incubated in the
medium without Fc-saxatilin and VEGF. Cell lysates were subjected to an im-
munoblot analysis with antibodies against either phospho-Src, Src, or actin, as
indicated. Representative data from three separate experiments are shown. B)
Bands in the immunoblots were quantified using ImageJ and normalized to
actin (n=3); ***P < 0.0001 compared to vehicle only-treated control,
*P < 0.05 compared to VEGF-treated control.
Fig. 3. Fc–saxatilin attenuates the phosphorylation of Fak induced by VEGF. A)
HBMECs were treated with pretreated with vehicle (PBS, 0) or Fc-saxatilin (50,
100, or 300 ng/ml) in the basal medium (0.5% FBS) for 10min and treated with
VEGF (100 ng/ml) for 1 h. Control cells were incubated in the control medium
without Fc-saxatilin and VEGF. Cell lysates were subjected to an immunoblot
analysis with antibodies against either phospho-Fak, Fak, or actin, as indicated.
Representative data from three separate experiments are shown. B) Bands in the
immunoblots were quantified using ImageJ and normalized to actin (n=3);
*P < 0.05 compared to the vehicle only-treated control or VEGF-treated con-
trol.
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specific antibody showed the clear localization of claudin-5 to the
plasma membrane in areas of cell–cell contact. The expression of
claudin-5 at the membrane was disrupted by VEGF (Fig. 4C). The dis-
ruption of claudin-5 expression was recovered at the membrane region
of cell–cell contact by Fc–saxatilin (Fig. 4C). To determine whether this
change in claudin-5 expression was due to transcriptional regulation,
we performed real-time PCR. Claudin-5 mRNA was down-regulated by
VEGF and this downregulation was also inhibited by Fc–saxatilin
(Fig. 4D). These results suggest that the regulation of claudin-5 ex-
pression might contribute to the recovery of VEGF-induced endothelial
permeability by Fc–saxatilin.
4. Discussion
We showed that Fc–saxatilin prevents VEGF-induced permeability
by blocking the VEGF-induced reduction of claudin-5 in HBMECs. The
signaling mediators linking VEGF to vascular permeability were also
inhibited by Fc–saxatilin. We previously showed that Fc–saxatilin
blocks vascular leakage during ischemic stroke in mice. Our results
provide an additional mechanism underlying the protective effect of
Fc–saxatilin on the vascular barrier in the ischemic brain.
Disintegrins are family of small molecular weight proteins first
identified from viper venom. These proteins contain RGD (Arg-Gly-Asp)
or KGD (Lys-Gly-Asp) sequence motif that binds specifically to integrin
receptors and act as integrin antagonists. Since integrins contribute to
diverse physiological and pathological process by mediating cell-cell or
cell-extracellular matrix interaction, disintegrins have been demon-
strated to inhibit these processes such as platelets aggregation which is
essential in thrombosis and haemostasis. In addition, due to the specific
interaction with integrins, disintegrins could also interfere cell survival,
proliferation, migration, invasion which are important processes in
tumor development. Disintegrins thus have been exploited for the
development of therapeutics for the prevention of thrombosis and
cancer.
Fc–saxatilin, a disintegrin fusion protein binds to endothelial in-
tegrin αvβ3 with a high affinity and blocks signaling by interfering with
the interaction between integrins and their extracellular matrix ligands
(Choi et al., 2017). Integrin signaling exhibits cross-talk with VEGF
signaling in cells (Byzova et al., 2000; Mahabeleshwar et al., 2007). In
particular, integrin αvβ3 enhances VEGF signaling in endothelial cells
attached to its ligand, vitronectin, and promotes angiogenic program-
ming (Soldi et al., 1999). Integrin αvβ3 is up-regulated in the micro-
vessels of ischemic brains with increased VEGF (Abumiya et al., 1999).
The blockade of these integrins with RGD-containing peptides leads to
decreased vascular leakage following middle cerebral artery occlusion
in vivo (Shimamura et al., 2006). Consistent with these studies, the
VEGF-induced increase in the permeability of HBMECs was reduced to
the level in control cells by another integrin blocker, Fc–saxatilin
(Fig. 1).
Src is a member of the non-receptor tyrosine kinase family. Src is a
well-known downstream molecule linking VEGF signaling to vascular
permeability (Eliceiri et al., 1999). Activated Src is involved in in-
creasing vascular permeability by the modification of the actin cytos-
keleton and VE-cadherin mediated cell-to-cell junctions (Hu et al.,
2008; Mucha et al., 2003; Sun et al., 2012). The mechanism underlying
the direct regulation of claudin-5 by Src has not been clearly defined.
However, the phosphorylation of Src and downregulated expression of
claudin-5 are well-correlated with VEGF-induced BBB breakdown in
transient focal cerebral ischemia of rats (Bai et al., 2014). The activa-
tion of Src by VEGF leads to the phosphorylation and degradation of
VE-cadherin, an adherent junction protein (Dejana et al., 2008; Weis
et al., 2004). Interestingly, VE-cadherin phosphorylation has been
linked to a reduction in the expression of claudin-5 in endothelial cells
(Taddei et al., 2008). These findings suggest that VEGF may indirectly
Fig. 4. Fc–saxatilin attenuates the reduction in
claudin-5 expression induced by VEGF. A) HBMECs
were treated with pretreated with vehicle (PBS, 0) or
Fc-saxatilin (50, 100, or 300 ng/ml) in the basal
medium (0.5% FBS) for 10min and treated with
VEGF (100 ng/ml) for 24 h. Control cells were in-
cubated in the basal medium without Fc-saxatilin
and VEGF. Cell lysates were subjected to an im-
munoblot analysis with antibodies against either
claudin-5, occludin, or actin, as indicated.
Representative data from three separate experiments
are shown. B) Claudin-5 bands in the immunoblots
from (A) were quantified using ImageJ and were
normalized to actin (n=3); ***P < 0.0001 com-
pared to vehicle only-treated control; *P < 0.05,
**P < 0.01 compared to VEGF-treated control. C)
HBMECs were treated with VEGF (100 ng/ml) in the
presence or absence of Fc–saxatilin (100 or 300 ng/
ml) for 24 h. Cells were stained with an antibody
(Ab) against claudin-5 (Green) and DAPI (blue; nu-
cleus) and images were obtained under a fluores-
cence microscope (Olympus, X400). Claudin-5 is
shown as a continuous line in the cell membrane
(arrows). In VEGF-treated cells, the intensity of
claudin-5 is severely reduced (Fc–saxatilin 0), and
the intensity is recovered in the Fc–saxatilin groups
(100 and 300 ng/ml). D) Total RNA was extracted
HBMECs treated with VEGF (100 ng/ml) in the pre-
sence or absence of Fc–saxatilin. Relative levels of
claudin-5 mRNA were measured by semi-quantita-
tive RT-PCR (n=4); *P < 0.05, **P < 0.01, or
***P < 0.0001 compared to vehicle only-treated
control or VEGF-treated control. (For interpretation
of the references to colour in this figure legend, the
reader is referred to the web version of this article.)
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regulate claudin-5 expression by controlling adherent junctions via Src.
The effect of Fc–saxatilin on claudin-5 expression in HBMECs could be
attributed to the inhibition of VEGF-Src-claudin-5 aixs.
Owing to the essential role of Src in VEGF-induced vascular per-
meability, its roles in the disruption of the BBB and brain damage in
stroke have been investigated in several studies. In animal models of
ischemic stroke, a genetic deficiency in Src reduces vascular perme-
ability as well as neuronal damage after stroke (Paul et al., 2001). In
this model, VEGF expression was correlated with vascular permeability.
The Src kinase inhibitors PP1 or PP2 consistently reduce the infarct size
of the ischemic brain and vascular permeability (Bai et al., 2014; Paul
et al., 2001; Zan et al., 2014). The results of the present study suggest
that Fc–saxatilin plays a role in reducing ischemia-induced vascular
leakage by inhibiting VEGF-induced Src activation.
Fak mediates integrin signaling and is involved in the formation of a
focal adhesion complex of endothelial cells on the matrix and cell mi-
gration. Fak phosphorylation is increased in response to VEGF stimuli
via an undefined mechanism (Abedi and Zachary, 1997). Considering
that Fc–saxatilin is a disintegrin with a high affinity to specific integrins
and that Fak is a direct downstream protein activated by integrin li-
gation, it could be hypothesized that the blockade of integrins by
Fc–saxatilin influences VEGF-induced Fak signaling in endothelial cells.
Several studies have demonstrated the cross-talk between integrins and
VEGF signaling regulates angiogenesis (Brakenhielm, 2007;
Mahabeleshwar et al., 2007). Additionally, endothelial-specific Fak
knockout mice have reduced VEGF-induced permeability and related
downstream signaling (Chen et al., 2012). In line with this, dominant-
negative Fak mutants exhibit the suppression of VEGF-stimulated per-
meability in vitro and in coronary vessels ex vivo (Wu et al., 2003). Our
results reveal that Fc–saxatilin blocks VEGF-induced Fak activity and
permeability, supporting the role of crosstalk between integrins and
VEGF signaling in brain endothelial cells. Taken together, this study
provides evidence for a possible mechanism in which Fc–saxatilin mi-
tigates vascular leakage in the ischemic mouse brain by regulating in-
tegrin–Fak signaling.
In conclusion, our results showed that Fc–saxatilin blocks brain
endothelial permeability induced by VEGF. Our findings indicated that
Fc–saxatilin is a potential candidate for the prevention of vascular
leakage in ischemic brains because VEGF is an important factor for the
disruption of the BBB in pathological conditions, including stroke.
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